This is an aggregated industry headline. Read the full story at FierceBiotech →
Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J
Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with metabolic dysfunction-associated steatohepatitis (MASH).
By FierceBiotech
· May 6, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
DealsBriefing
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
DealsFierceBiotech ↗
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product del…
DealsPharmaceutical Technology ↗
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…